Skip to main content

Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS)

Abstract

Background

The Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS) are patient-reported outcome measures developed to evaluate efficacy in clinical trials and clinical practice. The ESD is a daily electronic diary assessing symptom severity; the EIS is a weekly electronic diary assessing symptom impact. This study explored the importance of symptoms (ESD items) and impacts (EIS domains), perspectives on scoring algorithms, and clinically important difference (CID) thresholds to inform clinical trial score interpretation.

Methods

Endometriosis patients in Germany (n = 8) and the US (n = 17), and expert clinicians (n = 4) in Germany, the US, Spain, and Finland participated in semi-structured qualitative interviews comprising structured tasks. Interview transcripts were analyzed using thematic analysis techniques.

Results

Quality and severity of endometriosis-associated pelvic pain varied considerably among patients; some experienced pelvic pain daily, others during menstrual bleeding (dysmenorrhea) only. Patients and clinicians ranked “worst pelvic pain” as the most meaningful pain concept assessed by the ESD, followed by constant and short-term pelvic pain. Preferences for summarizing daily pain scores over the 28-day menstrual cycle depended on individuals’ experience of pain: patients experiencing pain daily preferred scores summarizing data for all 28 days; patients primarily experiencing pain during selected days, and their treating clinicians preferred scores based on the most severe pain days. Initial CID exploration for the “worst pelvic pain” 0–10 numerical rating scale (0–10 NRS) revealed that, for most patients, a 2- or 3-point reduction was considered meaningful, depending on baseline severity. Patients and clinicians ranked “emotional well-being” and “limitations in physical activities” as the most important EIS domains.

Conclusions

This study informs the use of the ESD and EIS as clinically relevant measures of endometriosis symptoms and their impact. Findings from the ESD highlight the importance of individual-patient assessment of pain experience and identify “worst pelvic pain” as the most meaningful symptom assessed. Aggregating scores over the 28-day menstrual cycle may inform meaningful endpoints for clinical trials. Diverse EIS concepts (e.g. impact on emotional well-being and physical activities) are meaningful to patients and clinicians, emphasizing the importance of evaluating the impact on both to comprehensively assess treatment efficacy and decisions.

Trial registration

Not applicable. Qualitative, non-interventional study; registration not required.

Background

Endometriosis is an estrogen-dependent disorder characterized by the presence of endometrial-like tissue outside the uterus, which induces a chronic inflammatory reaction [1, 2]. It affects approximately 10–15% of women, although the exact prevalence is unknown due to diagnostic delay, increasing to 30–50% among those with infertility [3,4,5]. Pelvic pain is the main symptom associated with endometriosis, which can present during vaginal bleeding (dysmenorrhea), during sexual intercourse (dyspareunia), or independent of vaginal bleeding (non-menstrual pelvic pain) [6]. Patients can also experience lower back pain or abdominal discomfort [6]. Endometriosis symptoms can affect a patient’s physical, mental, and social well-being, impairing quality of life [1, 7]. Endometriosis is a chronic disorder and although medical and surgical treatments can alleviate symptoms, 5–59% of women continue to experience pain following treatment, 11–19% of women experience no pain relief at all, and 17–34% experience recurrence of pain symptoms after treatment cessation [8,9,10].

In clinical trials, treatment effect is generally assessed by investigating change in endometriosis associated pelvic pain (EAPP) such as non-menstrual pelvic pain, dysmenorrhea, and dyspareunia [11, 12]. Considering the inherently subjective nature of these symptoms, and in the absence of biomarkers, they can only be rated appropriately by patients’ self-report using patient-reported outcome (PRO) measures. A systematic review of EAPP assessment has suggested that a visual analogue scale (VAS) or a numeric rating scale (NRS) adapted for endometriosis may optimize the assessment of EAPP in clinical research and practice and identified a potential gap in availability of measures developed on the basis of patient input [13]. Over the past few years several PRO measures have been developed for use to assess key clinical trial endpoints in the evaluation of endometriosis treatments addressing this gap, including the Endometriosis Symptom Diary [14] and the Endometriosis Pain Daily Diary (EPDD) [15]; both measures assessing similar concepts but with notable differences as described previously [14]. In conjunction measures have also been developed to assess the impact of endometriosis pain including the Endometriosis Daily Pain Impact Diary [16] and the Endometriosis Impact Scale (EIS) [14].

The measures of interest in this study, the ESD and EIS, were developed in accordance with scientific standards including FDA Guidance for Industry [17] and the European Medicines Agency (EMA) reflection paper [18]. The content of the ESD and EIS was developed based on a review of published literature, concept elicitation interviews with patients in the US, Germany, and France (n = 45), cognitive interviews with patients in the US and Germany (n = 31), and consultations with PRO and clinical experts throughout the development [14].

The ESD is a daily electronic diary which assesses the experience of endometriosis symptoms over the past 24 h mostly reported on a 0–10 NRS. The EIS is a weekly electronic diary comprising items assessing the impact of endometriosis symptoms on patients’ daily lives over the past 7 days using a 5-point VRS [14, 19]. The psychometric properties of the ESD and the EIS were further investigated in accordance with scientific standards in the Validation study for Endometriosis PRO (VALEPRO), a prospective, non-interventional study conducted in the US and Germany which supported the ESD and EIS scores as reliable, valid, and sensitive to change for investigating endpoints in endometriosis clinical studies [19, 20]. All validation work was conducted under consultation with health authorities. Both PROs were included in a phase IIb trial to further confirm their measurement properties under clinical trial conditions [21].

As a daily-completed, multi-item measure, patients’ daily responses to individual ESD items can be aggregated using multiple different scoring approaches. For example, data can be combined using scores either from every day or from selected days according to the relevance to the concept of interest, such as average pain or worst pain and summarized as either frequency, mean, range. For Patient Focused Drug Development, the priority of these endpoints for hierarchical testing should be patient informed [22, 23]. The cyclical nature of endometriosis and its symptomatic heterogeneity can contribute to significant variation in patient experience and perception of symptom impact, making careful consideration of endpoints defined by diaries essential [22]. There is limited available guidance on developing and translating daily assessments into meaningful, sensitive endpoints. In addition, to interpret these endpoints, a threshold for meaningful within patient change must be determined [23]. Quantitative approaches (including anchor based methods) remain the standard in identifying CID thresholds, however, qualitative methods have gained traction [24], and the importance of collecting patient insight into the concept of meaningful change is increasingly recognized [25]. Especially, qualitative input from patients living with endometriosis, alongside clinical insight, can inform data interpretation in a way that will be meaningful and resonate with patients [22].

This study sought to generate additional insights from patients with endometriosis and treating clinicians to inform the implementation of the ESD and the EIS in endometriosis clinical trials, especially informing clinical endpoint selection and score interpretation. The specific objectives of this study were to understand: (1) the ESD items and EIS domains that would inform the most meaningful clinical trial endpoints; (2) preferred scoring algorithms for aggregation of the daily responses of the ESD “worst pelvic pain” item; and (3) clinician and patient perspectives of meaningful change in the ESD “worst pelvic pain” score.

Methods

This was a multinational qualitative interview study conducted with patients with endometriosis and clinical experts treating patients with endometriosis. Qualitative and quantitative data were collected in the interview.

Recruitment

Four clinicians, one each from the US, Germany, Spain and Finland, were recruited via an in-house clinician database and by contacting national endometriosis associations. Eligibility criteria required the clinicians to be in clinical practice and regularly treating ≥ 5 patients with endometriosis per month. No formal ethical approval was required for the clinician interviews, but all participants provided written informed consent.

Patients were recruited from three clinical sites in the US and one clinical site in Germany through referral from clinicians participating in the ESPARIOS clinical trial (NCT02203331). Patients were referred based on pre-defined eligibility criteria, which were designed to allow comparability between the ESPARIOS study population and future endometriosis clinical trial populations. Patients were eligible for inclusion if they were a premenopausal female ≥ 18 years of age with their endometriosis diagnosis confirmed by laparoscopy or laparotomy within 10 years of the interview, and had experienced EAPP within 4 weeks of the interview. All patients provided informed consent and ethical approval of the protocol was received (New England IRB #16-062; Meridian Health IRB# #201701052J; Baden Württemberg ethics committee #F-2016-072).

Interview process

Interviews were conducted in line with accepted industry best practice [25,26,27,28]. Clinician interviews were conducted via telephone in the clinician’s native language, and lasted 45–90 min (median 57 min, mean 64 min) no more than 60 min; patient interviews were conducted face-to-face by a trained, female qualitative investigator in the participant’s native language and lasted between 45–105 min (median 66 min, mean 67.8 min). The ESD and EIS had been previously translated and linguistically validated in native endometriosis patients from US English to Spanish, German, and Finnish using industry standard methods [29, 30]. Separate semi-structured interview guides were developed for the clinician and patient interviews, and comprised a brief exploration of patients’ lived experiences of endometriosis, followed by four structured cognitive exploration tasks in line with the study objectives.

Cognitive exploration tasks

ESD item and EIS domain importance

To explore ESD item/EIS domain importance, clinicians were asked to allocate 100 points across each measurement concept or domain in a constant sum scaling task. Clinicians provided two distributions, one to represent the clinician perspective, and a second to represent their perception of the patient perspective (Example in Additional file 1: Additional Fig. 1). In comparison, patients were asked to rank the ESD items and EIS domains (Additional file 1: Additional Fig. 2) in order of relative importance from the patient’s own perspective. Patients were permitted to give two or more items/domains the same importance ranking if they wished. Responses from both clinicians and patients were used as a prompt for further discussion around the relative importance of the discussed ESD items/EIS domains.

Scoring algorithms for the ESD “worst pelvic pain” item

Clinician and patient insights were collected on appropriate algorithms for aggregation of the daily responses on the ESD “Worst overall pelvic pain” 0–10 NRS using four calendar depictions of potential scores to explore which was most meaningful (Additional file 1: Additional Fig. 3): mean score of the 7 worst days in the past 28 days (Score A), mean score of all 28 days (Score B), percentage of days with worst pain ≥ 7 in the past 28 days (Score C), or percentage of days with worst pain ≥ 4 in the past 28 days (Score D). Responses from clinicians and patients were used to evaluate preferences for score aggregation for informing the assessment of patient responses during a clinical trial.

ESD “Worst overall pelvic pain” 0–10 NRS cut-off scores

Patients described each level of pain, with particular detail provided about the patient experience at the two pre-suggested 0–10 NRS cut-off points: 0–10 NRS 4 (moderate EAPP) and 0–10 NRS 7 (severe EAPP) [31]. This informed the appropriateness of scoring algorithms that included scores of ≥ 4 and ≥ 7 (as detailed in Score C and Score D; Additional file 1: Additional Fig. 3). In addition, clinicians and patients described the impact that “Worst overall pelvic pain” had on the patients.

Clinicians were asked, which values of the ESD “Worst overall pelvic pain” 0–10 NRS they considered to represent for “mild,” “moderate,” and “severe” pain and to discuss the clinical meaningfulness of scores > 4 and > 7. To facilitate discussion, study participants presented with a blank 0–10 NRS (Additional file 1: Additional Fig. 4) and asked to use pre-defined and/or blank labels to assign descriptions to points on the scale.

Meaningful change on the ESD “worst pelvic pain” 0–10 NRS

Clinicians and patients were asked to describe the score changes on the ESD “Worst overall pelvic pain” 0–10 NRS that would be considered meaningful or important in the context of receiving endometriosis treatment. To facilitate this, patients were shown the ESD “Worst overall pelvic pain” 0–10 NRS marked with various changes in score (Additional file 1: Additional Fig. 5), and asked to describe what such a change would mean to them in terms of how they would feel or function. Where possible, this discussion took place in the context of true changes patients had experienced, while clinicians described meaningful change scores both from a clinical management perspective and from the perspective of their patients.

Data analysis

Interviews were audio recorded, transcribed verbatim, and translated to English where required. Participants were allocated a code to allow data to be reported anonymously, and interview transcripts were reviewed in full to remove all identifying information. Qualitative data were subject to thematic analysis [32, 33] facilitated by use of ATLAS.ti v7.5 software; quantitative data were explored using descriptive statistics in Microsoft® Excel.

Results

Study sample

Four clinicians from the US, Germany, Spain, or Finland (each n = 1) were interviewed. All worked within university hospitals and were involved in endometriosis diagnosis, treatment, and patient management. Overall, 25 patients with endometriosis from the US and Germany participated; demographic and clinical characteristics are presented in Table 1.

Table 1 Patient demographic and clinical characteristics

Patients’ experiences of pelvic pain related to endometriosis

Experiences of EAPP varied considerably between patients, with some patients experiencing pain every day and others only experiencing pain around the time of their menstrual period or during intercourse. Examples of patient pain profiles (mild, moderate/severe, and unpredictable) are shown in Table 2.

Table 2 Examples of three different patient pain profiles

ESD item importance

Patients and clinicians gave similar importance to each item of the ESD (Table 3). “Worst overall pelvic pain” (ESD item 1) was rated by all clinicians and most patients (n = 15/24; 63%) as the most or second-most important ESD item. Patients explained that “Worst overall pelvic pain” encompassed all of the pain types experienced in association with endometriosis, included pain during presence or absence of vaginal bleeding, and was therefore the pain that they experienced most often and had the greatest impact on their lives:

  • “It summarizes all the pain.” (US-16)

  • “[It’s the most important] because if I can't fix that, then I can't do my daily stuff.” (US-04)

  • “[This is] most important because I feel like this is a daily issue.” (US-06)

Table 3 Relative importance of ESD items/concepts reported by patients and clinicians

“Worst constant pelvic pain” was assigned the second highest priority overall for both clinicians and patients; one clinician described this pain type as “the most disabling for a woman.” Fourteen of 25 patients (56%) considered “Worst constant pelvic pain” as one of the top two most important pain types due it being a permanent “frustrating” presence in their lives and the type of pain most likely to interfere with their daily activities:

  • “I obviously think the constant pain is [most important] because […] it’s constant pain, it’s all the time.[…] It makes me unhappy, it makes me irritable.” (US-03)

  • “I can feel it every day, hour or minute. It is just always present.” (DE-03)

Other patients considered this item to be less important because they could anticipate their “Worst constant pelvic pain”, and had learned how to cope with it:

  • “Well, the constant I can deal with ‘cause I know it’s going to be there.” (US-11)

    “Worst short-term pelvic pain” received mixed views from patients and clinicians. Some patients ranked “Worst short-term pelvic pain” with high importance due to the severity and unpredictability of this pain type. Others considered the short-lived nature of the pain comparatively easier to cope with and thus of lesser importance:

  • “I have a pretty good pain tolerance. So, I know if I can just breathe through it for a minute, it goes away.” (US-04)

  • “This is the worst thing for me.[…] It is the most limiting for me, the fact that it is random or unpredictable, and it just shuts me off and kills any nice moments.” (DE-05)

  • “I may be sitting at my desk at work when all of a sudden the stabbing pain kicks in and I pinch my fingers on my desk and curl up with pain.” (DE-07)

There was some variability between the importance that patients assigned to the “Pain associated with bleeding” concept and “Pain during sexual intercourse” item. Patients who did not experience pain during sexual intercourse or did not experience differences in pain during bleeding days compared with non-bleeding days ranked these items of a comparably lower importance (Table 2). Clinician ratings were also comparably lower to overall worst pelvic pain, constant and short-term pain. For other patients, however, pain associated with bleeding or sexual intercourse were rated to be of highest importance. In addition, several patients found the “Pain during sexual intercourse” item important due to its impact not just on themselves, but also their partners.

  • “[Bleeding days] are the days where I am in the most pain and the most incapacitated.” (US-03)

  • “I put ‘Pain associated with bleeding’ [as rank] 7 because for me I never really had pain with bleeding, so that to me is not a factor.” (US-01)

  • “I think [‘Pain due to sexual intercourse’] is just very important to me because that's something that I would like to give [my husband].[…] It's frustrating because I can't give him that one particular thing that he really desires as much as he would like.” (US-02).

Patients and clinicians interviewed both ranked “Avoidance of sexual intercourse” and “Pain medication usage” as ESD items of minor importance to them. However, some patients rated “Pain medication usage” highly due to concerns related to addiction or side effects.

EIS domain importance

Clinicians mostly agreed with patients on the relative importance of the different EIS concepts (Table 4). Patients and clinicians ranked “Negative impact on your emotional well-being” to be of high importance, as their emotional response to EAPP, e.g. feeling tearful, irritable and angry, had a substantial impact on their ability to undertake any daily activity or to socialize.

  • “When I don’t feel good, I am in a bad mood. It’s easy for me to be irritable or stressed out. And so, that affects my family and it affects work.” (US-13)

  • “When I'm not in a good mood I don't want to be around people. I'm a social butterfly so people don't understand when I don't want to be around them because I'm in pain.” (US-02)

Table 4 Relative importance of EIS concepts reported by patients and clinicians

“Limitations in your physical activities” also ranked highly in the patients’ ratings:, suggesting, if they could not move, they could not work, socialize, or take part in leisure activities.

  • “Ok. My first one I put as most important was physical activities, which is my exercise, the exercise, like six days a week, so for me, even if I’m all day in my job. So for me that is the most important, because if I don’t exercise, and if I take out two days of exercise, I get crabby, it’s like I just need that stimulation or something.” (US-01)

  • “I want to be able to go out and play with my son without needing to come in and sit down. I want to be able to sit through a movie […] I will have to change positions five hundred thousand times because it gets uncomfortable.” (US-03)

This ranking was echoed by clinicians. One clinician noted that “one thing is a consequence of the other,” and another clinician stated that if patients can go about their physical activities, they have “fewer emotional problems”.

The EIS “Other limitations” domain includes items assessing social and leisure activities, paid work or study, household activities, difficulty concentrating, and/or difficulty sleeping. Of these items, patients considered difficulty sleeping and an inability to work or socialize as important items.

  • “I want to be able to work continuously and not have to miss shifts and miss out on money. I do still have bills. But when it happens I have no choice but to leave.” (US-11)

  • “Sleeping; oh my goodness, yeah. I've been asleep and it's like a sharp—it hits me, it wakes me up out of my sleep. So, yeah, that's—it's not fun.” (US-05)

Overall, patients and clinicians considered “Limitation in sexual activities” as comparably less important to other domains. Clinicians described “Limitation in sexual activities” as not of high importance to some patients. However, for some patients this was a very important concern due to the impact on their partner as well as themselves.

  • “That would make me happier, number one it would make my husband happier, make my family happier […] because when you have two happy parents you would be happier.” (US-03)

  • “It’s not that it’s not important, but everything else came prior.” (US-16)

Scoring algorithms for the ESD “worst pelvic pain” 0–10 NRS

Overall, patients expressed mixed preferences regarding the four different scoring algorithms proposed for the “Worst overall pelvic pain” 0–10 NRS for aggregating the daily scores over a 28 day period. Individual preferences seemed dependent on the patient’s own pain profile. Patients’ and clinicians’ perceived advantages and disadvantages of each algorithm are presented in Table 5.

Table 5 Comparison of four algorithms for aggregation of daily responses for ESD “worst pelvic pain” NRS

ESD “Worst overall pelvic pain” 0–10 NRS cut-off scores

Patients and clinicians described “mild”, “moderate”, and “severe” pain related to the

0–10 NRS. In general patients and clinicians reported the mild/moderate boundary to be at approximately 4 and the moderate/severe boundary to be at approximately 7 on the 0–10 NRS (Fig. 1).

Fig. 1
figure1

Patient and clinician uses of “mild,” “moderate,” and “severe” with the ESD NRS. Green cells indicate application of “mild” descriptor to NRS value, yellow cells indicate application of “moderate” descriptor to NRS value, red cells indicate application of “severe” descriptor to NRS value, and gray cells indicate no descriptor was allocated to the NRS value. Total scores at the bottom of the figure indicate the number of patients allocating each label to each NRS value. ESD = Endometriosis Symptom Diary; NRS = numerical rating scale

Scores < 4 were considered to be mild and not impairing patients’ lives, whereas limitations became more apparent at a score of 4 on the 0–10 NRS. Clinicians suspected that patients would seek treatment at this point; indeed, many patients reported the use of non-steroidal anti-inflammatory drugs at scores > 4. Most patients reported “noticing” the pain at this level, although the majority did not consider themselves to be functionally impaired, commenting that “you can still do what you need to do, but you don’t feel good doing it” (US-03). Some patients noted that as they were conscious of pain, their mood would be affected.

In general, clinician perceptions of scores of 7 on the 0–10 NRS were more severe than those provided by patients; clinicians considered scores of 7 on the 0–10 NRS to be severely limiting and to require immediate medical attention. Patients, however, reported that this level of pain was just “the start of a peak” (US-15) and would subsequently get considerably worse. Some patients reported considerable physical limitations at a score of 7 on the 0–10 NRS and described reducing their activities to only those that were most necessary. Scores of 7 were also described as a turning point in patients’ moods, with patients feeling miserable and withdrawn. A summary of patient descriptions of each point on the 0–10 NRS is presented in Table 6.

Table 6 Patients’ descriptors used for the ESD “worst pelvic pain” 0–10 NRS

Meaningful change on the ESD “Worst overall pelvic pain” 0–10 NRS

Clinicians described the minimum score change on the 0–10 NRS that would be considered meaningful following treatment for endometriosis to be dependent on the baseline score, as “it all depends on what level you are coming from” (Clin-GER) (Table 7).

Table 7 Patient feedback on meaningful change on the ESD “Worst pelvic pain” 0–10 NRS

Patient ratings supported this statement. When discussing meaningful change from a score of 8 on the 0–10 NRS, most patients perceived a 3-point reduction as being meaningful

  • “On level 8, I cannot do anything, but on level 5, I could do almost everything although I would constantly feel right on the borderline to taking pain medication. I imagine that being on level 5, I might be free of pain at some points by taking pain medication.” (DE-06)

    When discussing meaningful change from a score of 5 on the 0–10 NRS, most patients described a 2-point reduction as being meaningful. One patient described a change in score from 5 to 3 as “life-changing” (US-03) and another commented that “even though it might not be fun, I could go to work normally and lead a regular social life” (DE-04).

    When discussing meaningful change from a score of 3 on the 0–10 NRS, some patients commented on the limited opportunity for meaningful change a score of 3 on the 0–10 NRS was already considered representative of “mild” pain. Other patients concluded that if their pain were “only” at a score of 3 on the 0–10 NRS, treatment would need to remove pain entirely in order to make a meaningful difference.

  • “…I mean if I was at a 3 every day I’d be great.[…] A 3 I wouldn’t even notice.[…] Any change would be fine…” (US-01)

  • “Well I guess level 2 would be fine… but really if it were me personally, I wouldn’t go on a 12-week treatment if I were on pain level 3. I feel that the effort I would put into that treatment would be more than the difference between levels 0 and 3." (DE-08)

Discussion

The findings from this study supplement prior validation studies of the ESD and EIS [14, 19, 20] as fit-for-purpose measures of endometriosis symptoms and related impacts in clinical trials.

Participating patients had varied experiences of EAPP, including dysmenorrhea and dyspareunia, in line with previous findings [13, 15], and indeed our study found that some pain types, such as constant pain, short-term pain, pain associated with bleeding, or pain during sexual intercourse, were not experienced by all of the women interviewed.

Patients and clinicians prioritized “Worst overall pelvic pain” as an important measurement concept, regardless of whether it was associated with menstrual bleeding, with sexual intercourse, or neither. This finding is comparable with qualitative studies in other endometriosis patient populations that have identified both non-menstrual pelvic pain and pain during menstruation as important symptoms of endometriosis for a treatment to address [15, 34]. Therefore, a score assessing all aspects of pain related to endometriosis, such as the ESD “Worst overall pelvic pain” 0–10 NRS might be meaningful to support a key efficacy endpoint in endometriosis clinical trials.

When assessing the impact of EAPP, in line with previous findings, [15, 16] the domains “Negative impact on your emotional well-being” and “Limitations in physical activities” were considered most meaningful to patients and clinicians. Clinicians in particular emphasized the degree of association between these two different concepts and the importance of evaluating and reporting changes in the impact on both physical activity limitations and emotional well-being to inform the selection of treatment options.

Overall, all scoring algorithms used to aggregate the daily ratings over the 28-day menstrual cycle were found to have potential advantages. In addition, some general preferences by clinicians for selecting a subset of days within the 28-day cycle was observed in concordance with an understanding that pain levels frequently vary during the menstrual cycle and that days where the most severe pain was experienced might be most important to women with endometriosis. Patients did not identify a single “best” scoring option: those who experienced pain daily tended to prefer an aggregation of scores from all days within the 28-day cycle; those whose pain did not occur daily or whose pain varied in severity throughout the month generally preferred a score that included only the most severe days. Definitions of those “most severe pain days” were explored to understand the appropriateness of proposed scoring algorithms. Most patients considered a “severe” level of pain as ≥ 7″ on the 0–10 NRS, consistent with findings in the literature [13]. Patient opinions were mixed with regards to whether scores ≥ 4 or scores ≥ 7 were most important for a treatment to address. This result is in line with previous findings that “mild” “moderate” and “severe” verbal pain categories may correspond to different VAS and NRS values in the same patient on different occasions [35, 36].

The final objective of this study was to explore the changes in “worst pelvic pain” scores that patients understand as clinically meaningful (i.e., resulting in a meaningful improvement in how they feel or function). In general, patients and clinicians identified a greater degree of improvement as meaningful for higher baseline pain levels than for lower baseline pain levels. Slightly greater than the minimal clinically important difference of 10 mm on the 100 mm VAS for assessing endometriosis-associated pelvic pain presented by Gerlinger et al. [37], a 2-point change on the ESD “Worst overall pelvic pain” 0–10 NRS was mentioned by some of the study participants to capture meaningful changes. When setting a priori responder definitions, however, the expected baseline pain severity of the sample is recommended to be considered [36].

Patients frequently described the relationship between EAPP and physical limitations and the relationship between EAPP and impact on emotional well-being. These findings, and those reported elsewhere [14, 15, 19, 20, 38, 39], highlight that patients’ emotional well-being is directly influenced by pain severity and not just secondary to other aspects of endometriosis, such as avoidance of sexual intercourse and any associated feelings of guilt. Therefore, the impact of endometriosis on emotional well-being can be considered a proximal impact of EAPP. Indeed, this study found that “negative impact on emotional well-being” was considered of comparable importance as “limitation in physical activities” when assessing the most important EIS domains for measurement. This reflects the recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), which list physical functioning and emotional functioning as core outcome domains that should be considered when designing clinical trials for chronic pain conditions [40].

As a major limitation of this study it must be noted that cognitively complex themes were discussed with patients who are not expected to have a background in this type of research. Additionally, the topic of meaningful differences on the ESD scale might have been difficult to conceptualize for any participants who had not experienced recent changes in pain. Also a difference in familiarity with the ESD and EIS existed, depending on whether patients had participated in the clinical study BAY98-7196/15832, or not; this was mitigated by all participants completing the ESD for 7 days prior to interview and the EIS once before and on the day of the interview. However, no obvious differences in findings between these two subgroups emerged. Qualitative exploration can be influenced by the researchers’ personal biases; this was mitigated by using highly experienced interviewers and the formal structure in tasks removed some elements of interpretation. Although patients and clinicians from several countries were included, the small sample sizes did not allow comprehensive cultural comparisons. Furthermore, the small sample size and the heterogeneity in endometriosis symptoms experienced means that results are not universally generalizable and should be considered in the context of other relevant qualitative and quantitative studies. An area for further exploration may be to investigate the importance of dyspareunia and limitations on sexual activities, given the polarization in importance ratings demonstrated by women in this study.

Conclusions

The ESD and EIS provide clinically relevant assessments of endometriosis symptoms and the impact of endometriosis on patients’ lives. Insights from patients and clinicians highlight the importance of “worst pelvic pain” as measured by the ESD, and suggest that aggregating scores over the 28-day menstrual cycle can support efficacy assessments in endometriosis treatment trials. A reduction of 2–3 points on the ESD “worst pelvic pain” 0–10 NRS was considered meaningful to most patients, but patient interpretations of meaningful change were also reported as being dependent on baseline pain severity. Findings from this study highlight the importance of assessing the impact of treatments on physical limitations and emotional well-being of patients to fully understand treatment efficacy.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

B&B:

Biberoglu and Behrmann

CID:

clinically important difference

CPSSS:

composite pelvic pain and Symptoms Scale

EAPP:

endometriosis associated pelvic pain

EHP:

Endometriosis Health Profile Questionnaire

EIS:

Endometriosis Impact Scale

EMA:

European Medicines Agency

ESD:

Endometriosis Symptom Diary

ESPARIOS:

Efficacy and Safety of Progestin and Aromatase Inhibitor Intravaginal Ring in endometriOSis

FDA:

US Food and Drug Administration

IMMPACT:

Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials

IRB:

Institutional Review Board

MCID:

minimal clinically important difference

NRS:

Numerical Rating Scale

NSAID:

non-steroidal anti-inflammatory drug

PRO:

patient-reported outcome

SD:

standard deviation

VALEPRO:

validation study for endometriosis PRO

VAS:

Visual Analog Scale

VRS:

Verbal Rating Scale

References

  1. 1.

    Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E. Endometriosis ESIGf, Endometrium Guideline Development G: ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod. 2005;20:2698–704.

    Article  Google Scholar 

  2. 2.

    Johnson NP, Hummelshoj L. World Endometriosis Society Montpellier C: consensus on current management of endometriosis. Hum Reprod. 2013;28:1552–68.

    Article  Google Scholar 

  3. 3.

    Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D’Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92:68–74.

    Article  Google Scholar 

  4. 4.

    Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6:34–41.

    Article  Google Scholar 

  5. 5.

    Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125:55–62.

    CAS  Article  Google Scholar 

  6. 6.

    Leyland N, Casper R, Laberge P, Singh SS. Sogc: endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32:S1-32.

    Article  Google Scholar 

  7. 7.

    Klein S, D’Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? a prospective Belgian study. Reprod Biomed Online. 2014;28:116–24.

    Article  Google Scholar 

  8. 8.

    Dunselman G, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne A, Kiesel L, Nap A. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–12.

    CAS  Article  Google Scholar 

  9. 9.

    Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017;108:125–36.

    Article  Google Scholar 

  10. 10.

    Practice Committee of the American Society for Reproductive M. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril. 2014;101:927–35.

    Article  Google Scholar 

  11. 11.

    Hirsch M, Duffy JMN, Kusznir JO, Davis CJ, Plana MN, Khan KS, Duffy JMN, Farquhar C, Hirsch M, Johnson N, Khan K. Variation in outcome reporting in endometriosis trials: a systematic review. Am J Obstet Gynecol. 2016;214:452–64.

    Article  Google Scholar 

  12. 12.

    Jensen JT, Schlaff W, Gordon K. Use of combined hormonal contraceptives for the treatment of endometriosis-related pain: a systematic review of the evidence. Fertil Steril. 2018;110(137–152):e131.

    Google Scholar 

  13. 13.

    Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update. 2015;21:136–52.

    Article  Google Scholar 

  14. 14.

    Gater A, Taylor F, Seitz C, Gerlinger C, Wichmann K, Haberland C. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary and Endometriosis Impact Scale. J Patient Rep Outcomes. 2020;4:1–17.

    Article  Google Scholar 

  15. 15.

    van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. Health Qual Life Outcomes. 2018;16:3.

    Article  Google Scholar 

  16. 16.

    Wyrwich KW, O’Brien CF, Soliman AM, Chwalisz K. Development and validation of the endometriosis daily pain impact diary items to assess dysmenorrhea and nonmenstrual pelvic pain. Reprod Sci. 2018a;25:1567–76.

    Article  Google Scholar 

  17. 17.

    Food and Drug Administration: Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labelling claims. 2009. https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Last accessed 12/02/2020.

  18. 18.

    European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the reglulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. https://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf. Last accessed 12/02/2020.

  19. 19.

    Gater A, Moore A, Coon CD, Chen WH, Wichmann K, Hartisch C, Filonenko A, Seitz C, Gerlinger C. Measuring the symptoms and impacts of endometriosis: psychometric validation of the Endometriosis Symptom Diary and Endometriosis Impact Scale. Value Health. 2015;18:A26.

    Article  Google Scholar 

  20. 20.

    Gater A, Wichmann K, Seitz C, Gerlinger C, Taylor F, Chen WH, Filonenko A. Assessing the content validity of the endometriosis symptom diary and endometriosis impact scale. Value Health. 2014;17:A198–9.

    Article  Google Scholar 

  21. 21.

    Haberland C, Gater A, Wessiepe D, Schmitz H, Gerlinger C, Seitz C. Psychometric validation of the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS): findings from an interventional study. In: International Society for Quality of Life Research (ISOQOL) 25th annual conference. Dublin, Ireland. 2018.

  22. 22.

    Gater A, Coon CD, Nelsen LM, Girman C. Unique challenges in development, psychometric evaluation, and interpretation of daily and event diaries as endpoints in clinical trials. Ther Innov Regul Sci. 2015;49:813–21.

    Article  Google Scholar 

  23. 23.

    PATIENT-FOCUSED DRUG DEVELOPMENT GUIDANCE PUBLIC WORKSHOP. Methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. https://www.fda.gov/media/116277/download.

  24. 24.

    Coon CD, Cappelleri JC. Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci. 2015;50:22–9.

    Article  Google Scholar 

  25. 25.

    Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3:16.

    Article  Google Scholar 

  26. 26.

    Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2—assessing respondent understanding. Value Health. 2011;14:978–88.

    Article  Google Scholar 

  27. 27.

    Food and Drug Administration: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders: Patient-Focused Drug Development. Collecting comprehensive and representative input. 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Last accessed 12/02/2020.

  28. 28.

    Patient-Focused Drug Development. Methods to identify what is important to patients guidance for industry, food and drug administration staff, and other stakeholders. https://www.fda.gov/media/131230/download.

  29. 29.

    Wild D, Eremenco S, Mear I, Martin M, Houchin C, Gawlicki M, Hareendran A, Wiklund I, Chong L, von Maltzahn R, et al. Multinational trials—recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report, vol 12. 2009.

  30. 30.

    Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Translation ITFf, cultural A: principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health. 2005;8:94–104.

    Article  Google Scholar 

  31. 31.

    Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain. 2000;16:22–8.

    CAS  Article  Google Scholar 

  32. 32.

    Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.

    Article  Google Scholar 

  33. 33.

    Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage; 2011.

    Google Scholar 

  34. 34.

    Germain N, Aballéa S, Andersson FL, Korchagina D, Hawken NA, Toumi M. PIH21—patients’ preferences related to treatments for endometriosis-related pain: results of a discrete choice experiment in the UK. Value Health. 2017;20:A523.

    Article  Google Scholar 

  35. 35.

    Aicher B, Peil H, Peil B, Diener HC. Pain measurement: Visual Analogue Scale (VAS) and Verbal Rating Scale (VRS) in clinical trials with OTC analgesics in headache. Cephalalgia. 2012;32:185–97.

    CAS  Article  Google Scholar 

  36. 36.

    Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, Kvarstein G, Stubhaug A. Assessment of pain. Br J Anaesth. 2008;101:17–24.

    CAS  Article  Google Scholar 

  37. 37.

    Gerlinger C, Schumacher U, Faustmann T, Colligs A, Schmitz H, Seitz C. Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials. Health Qual Life Outcomes. 2010;8:138.

    Article  Google Scholar 

  38. 38.

    Vannuccini S, Lazzeri L, Orlandini C, Morgante G, Bifulco G, Fagiolini A, Petraglia F. Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. J Psychosom Obstet Gynecol. 2017;39:315–20.

    Article  Google Scholar 

  39. 39.

    Laganà AS, La Rosa VL, Rapisarda AMC, Valenti G, Sapia F, Chiofalo B, Rossetti D, Ban Frangež H, Vrtačnik Bokal E, Vitale SG. Anxiety and depression in patients with endometriosis: impact and management challenges. Int J Women’s Health. 2017;9:323–30.

    Article  Google Scholar 

  40. 40.

    Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106:337–45.

    Article  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Louise Humphrey for her contribution to the conception of this study. Dr. Daniela Hornung and Ursula Schaal at Diakonissenkrankenhaus Karlsruhe-Rüppurr; Dr. Stephen G Swanson, Hannah Hernandez, and Jennifer Lund at the Women's Clinic of Lincoln; Dr. Kirk Brody and Yvonne Chester at Chattanooga Medical Center; and Dr. Mark G Martens and LaShawn Jenkins at Meridian Hospitals Corporation are acknowledged for their support in patient identification and protocol implementation. Ulrike Röth is acknowledged for her support in data collection. Sophie Doran, of DRG Abacus, is acknowledged for medical writing support on the manuscript. The authors thank all patients who participated in this study.

Funding

Funding for this study was provided by Bayer AG, including collection, analysis, and interpretation of data. Medical writing support was also funded by Bayer AG and provided by DRG Abacus and Huntsworth Health.

Author information

Affiliations

Authors

Contributions

HK, TW, CH, HS, and CG designed the study protocol. HK, NA, and AT implemented the study and performed data collection and analyses. CH, HS, CG, CS, and AG reviewed the study findings and interpretations. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Claudia Haberland.

Ethics declarations

Ethics approval and consent to participate

The study protocol was reviewed and approved by New England IRB #16-062; Meridian Health IRB# #201701052J; Baden Württemberg ethics committee #F-2016-072). All participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

Helen Kitchen and Natalie Aldhouse are employees of DRG Abacus, a health economics and outcomes research company that consults with various pharmaceutical companies. At the time of his involvement Thomas Willgoss was an employee of DRG Abacus. Andrew Trigg and Adam Gater are employees of Adelphi Values, a health economics and outcomes research company that consults with various pharmaceutical companies. Claudia Haberland, Heinz Schmitz, Christoph Gerlinger, and Christian Seitz are employees of Bayer AG. Bayer AG has commissioned DRG Abacus and Adelphi Values to consult on PRO measurement for endometriosis.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1

. Examples of completed ranking tasks and material used for cognitive exploration tasks.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kitchen, H., Seitz, C., Trigg, A. et al. Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Health Qual Life Outcomes 19, 7 (2021). https://doi.org/10.1186/s12955-020-01579-7

Download citation

Keywords

  • Endometriosis
  • Endometriosis Symptom Diary (ESD)
  • Endometriosis Impact Scale (EIS)
  • Women’s health
  • Patient-reported outcome measures
  • Patient preference
  • Qualitative research
  • Clinically important difference (CID)
\